Paxil Birth Defect Lawsuit Referrals Being Offered Through Resource4thePeople
New medical research study adds to body of data raising concerns about anti-depressant use and birth defects. Free legal consultations are now available to provide legal options available to these families. http://www.resource4thepeople.com/defectivedrugs/paxil.html
San Diego CA (PRWEB) February 20, 2013
Resource4thePeople announced today that in the wake of new findings* showing that the use of Paxil may be putting pregnant mothers at higher risk of having an infant with birth defects that it is offering referrals to free consultations by lawyers experienced in defective drug litigation.
Paxil is one of the best-selling of the most recent class of anti-depressants known as selective serotonin reuptake inhibitors, or SSRIs. The medications moderate chemical messengers in the brain by blocking the reabsorption of the neurotransmitter serotonin.
“This recent study by respected researchers showing that the use of Paxil and some other antidepressants during pregnancy is associated with increased risks of miscarriage, birth defects, preterm birth, newborn behavioral syndrome, persistent pulmonary hypertension of the newborn and possible longer term neurobehavioral effects has caused some families to contact us about their legal rights,” said Resource4thePeople.
“Our decision to begin offering these links comes from the fact that we believe that all families should have complete access to the legal rights that they may enjoy for pain and suffering, loss of wages, medical costs and other expenses attributed to factors that were not of their making.
“Therefore we have set up referrals to experienced legal teams who are experienced in this area of the law and will be available to provide a free consultation in which the merits of each situation can be analyzed and the legal options available detailed.”
For a free consultation, click on this link:
Links between the use of anti-depressants such as Paxil and birth defects in mothers who used the medications while pregnant have been recognized by the Food and Drug Administration since 2005.**
Now, the latest medical research study about these side effects was recently published in the Human Reproduction Oxford Journal, January, 2013 edition,* which confirms fears of increased birth defect risks detailed in FDA health warning communications.
This finding comes directly from the article:
“Antidepressant use during pregnancy is associated with increased risks of miscarriage, birth defects, preterm birth, newborn behavioral syndrome, persistent pulmonary hypertension of the newborn and possible longer term neurobehavioral effects. There is no evidence of improved pregnancy outcomes with antidepressant use.”
These findings came in response to the research’s study question: “What is the current literature on the safety and efficacy of selective serotonin reuptake inhibitor (SSRI) use in infertile women?”
Resource4thePeople notes that these concerns about increased risk of birth defects as a result of Paxil use also have been echoed by the Mayo Clinic, which posted the following warning about Paxil use by pregnant women:***
“Antidepressants and pregnancy: Some antidepressants may harm your unborn child if you take them during pregnancy or while you’re breast-feeding. Paxil in particular appears to increase the risk of birth defects, including heart and lung problems. If you’re taking an antidepressant and you’re considering getting pregnant, talk to your doctor or mental health provider about the possible dangers. Don’t stop taking your medication without contacting your doctor first.”
Resource4thePeople also notes that one of the most recent Paxil birth defects lawsuits making such allegations was filed on October 19th, 2012.****
In that case a family is attributing the death of their baby daughter to a birth defect in her heart that the couple claim was caused by the use of Paxil and other anti-depressants by the mother during her pregnancy to fight depression, according to the court documents in the case.
“In an attempt to further inform consumers about the increased risk of serious side effects that have been attributed to Paxil and other SSRIs, we are also compiling a data bank making information about these medications and their manufacturers available to patients on our web site,” said Resource4thePeople.
Included in this information bank are updates on Paxil litigation, the findings of medical research studies, health advisories, warnings and recalls by the FDA and news reports involving the affected products.
“One of the important pieces of information we think that users of Paxil and other antidepressants should be aware of is the fact that Paxil’s manufacturer, giant pharmaceutical GlaxoSmithKline, agreed to pay $3 billion to the federal government to settle allegations over its marketing and sales of Paxil and other products,” said Resource4thePeople.
Information about this settlement**** is included in this data bank, reflecting the U.S. Justice Department’s announcement of what it described as massive health care fraud:
“GSK agreed to plead guilty to a three-count criminal information, including two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration (FDA).
Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK´s U.S. president and board of directors.
“GSK will also pay $2 billion to resolve its civil liabilities with the federal government under the False Claims Act, as well as the states. The civil settlement resolves claims relating to Paxil, Wellbutrin and Avandia, as well as additional drugs, and also resolves pricing fraud allegations.”
**** Case # 2:2012cv05962 U.S. District Court, Eastern District of Pennsylvania
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10444251.htm